

PainChek secures initial Sabra US care facilities

- PainChek secures an initial two commercial contracts under the Sabra Master Services Agreement
- New three-year deployments in two 'Traditions' memory care facilities
- Initial evidence of opportunity in US pipeline – expansion targeted into the rest of the Sabra 20,000 bed network
- IOWA clinic presented the successful PainChek FDA clinical trial results at the Argentum conference in Nashville, Tennessee in May 2026

Sydney, Australia, 4 June 2026 – PainChek Ltd (ASX: PCK), developer of the world's first AI-powered pain assessment and monitoring application, is pleased to announce it has secured its first initial commercial contracts within the Sabra group, from the 'Traditions' memory care homes in the US, under the Master Services Agreement announced on 14 April 2026. The two contracts are both three-year deployments targeted for use in the skilled nursing sector where there are high levels of people living with dementia.

The PainChek team is focused on expanding the US sales pipeline, negotiating with additional Sabra Health Group homes, whilst also engaging with another large US provider specialising in the memory care sector for people living with dementia. These new opportunities stemmed from the recent attendance at US conferences, including the Argentum conference in Nashville, Tennessee in May 2026, where collaborators from the IOWA clinic presented the PainChek FDA successful clinical trial outcomes to an audience of memory care and skilled nursing providers.

PainChek entered into a Master Services Agreement in April 2026 with Sabra Health Care REIT, Inc. (Nasdaq: SBRA) ("Sabra"), a leading owner of healthcare real estate assets across North America, that will see PainChek funded for as many as 20,000 beds across Sabra's 329 skilled nursing, long-term care and senior housing facilities.

Philip Daffas, CEO of PainChek, commented:

"We are delighted to see the rapid uptake and significant growing interest from the US skilled nursing and memory care sector, which is where PainChek can provide the greatest impact. Today, more than three million US nursing home residents are currently diagnosed with Alzheimer's disease and related dementias (ADRD)¹ and for whom pain assessment and pain management is a daily struggle. PainChek is the only FDA cleared medical device to assess pain for people living with dementia.

The Sabra agreement facilitates the accelerated uptake of PainChek across Sabra's 20,000 bed network of long-term care and senior housing facilities. This model is also a blueprint for PainChek in the US and transferrable to other major US-based real estate investment trusts who own large numbers of long-term care and senior living facilities."

The agreement represents a strategic commercial milestone for PainChek, establishing a repeatable, capital-light go-to-market mechanism that will facilitate broad PainChek adoption across Sabra-owned senior housing communities. Under the agreement, Sabra will fund the cost of PainChek's solution on behalf of its operating partners, significantly reducing barriers to adoption at the operator level.

Sabra has a market capitalisation of approximately \$5 billion, placing it among the larger specialised healthcare REITs in North America, having more than 36,000 beds or units in the US and Canada.

While the financial impact of the two new commercial agreements is not considered to be material, it is indicative of the potential for PainChek's solution to be deployed across the major US aged care sector.

This announcement has been approved for release by the Board.

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

¹ <https://pmc.ncbi.nlm.nih.gov/articles/PMC10796080/>

About Sabra Health Care

Sabra Health Care REIT, Inc. is a U.S.-based healthcare real estate investment trust (REIT) that owns and invests in properties serving the healthcare and senior-care sector. Founded in 2010 and headquartered in Tustin, California, Sabra's portfolio includes long-term care (skilled nursing) facilities, senior housing communities, and behavioural health and specialty hospitals across the United States and Canada.

<https://sabrahealth.com/>

About PainChek

PainChek® is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, USA, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom.

PainChek® has contracts with over 2,000 aged care facilities, with more than 20,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centers have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>